GEN.WAR Genomed S.A.

Healthcare Diagnostics & Research Warsaw Stock Exchange
37.20 PLN
Close of Oct 29, 2026
Market cap
PLN 49.2M
P/E
13.3x
P/B
4.24x
ROE
6.6%
Dividend yield
2.25%
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GEN.WAR undervalued?

Graham number
Price37.20
Graham value23.50
Premium58.3%

GEN.WAR trades 58.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genomed S.A. fundamental analysis

8 of 22 checks passed

ROE 0/2

Low return on equity (6.6%), below 10%.

ROA 0/1

Return on assets (5.0%) is below the industry median (5.5%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (223.0%) is above the industry median (33.8%).

Revenue Growth 2/2

Revenue grew 12.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 75.2x against interest expense, well covered.

PE vs Market 0/1

PE (13.4x) is above the market median (11.6x).

PE vs Industry 0/1

PE (13.4x) is above the industry median (11.6x).

PBV 0/1

Price to book (4.3x) is above the industry median (2.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 57.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 32.5%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Genomed S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genomed S.A.

Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company's diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various…

Full company profile